PL3781563T3 - Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie - Google Patents

Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie

Info

Publication number
PL3781563T3
PL3781563T3 PL19791794.1T PL19791794T PL3781563T3 PL 3781563 T3 PL3781563 T3 PL 3781563T3 PL 19791794 T PL19791794 T PL 19791794T PL 3781563 T3 PL3781563 T3 PL 3781563T3
Authority
PL
Poland
Prior art keywords
production
application
hpk1 inhibitors
hpk1
inhibitors
Prior art date
Application number
PL19791794.1T
Other languages
English (en)
Inventor
Xuebin Liao
Original Assignee
Zhuhai Yufan Biotechnologies Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai Yufan Biotechnologies Co., Ltd filed Critical Zhuhai Yufan Biotechnologies Co., Ltd
Priority claimed from PCT/CN2019/083499 external-priority patent/WO2019206049A1/en
Publication of PL3781563T3 publication Critical patent/PL3781563T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19791794.1T 2018-04-25 2019-04-19 Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie PL3781563T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810381425 2018-04-25
CN201810945948.2A CN110396087A (zh) 2018-04-25 2018-08-20 Hpk1激酶抑制剂、制备方法及其应用
CN201810946081.2A CN110396088B (zh) 2018-04-25 2018-08-20 Hpk1激酶抑制剂、制备方法及其应用
PCT/CN2019/083499 WO2019206049A1 (en) 2018-04-25 2019-04-19 Hpk1 inhibitors, preparation method and application thereof

Publications (1)

Publication Number Publication Date
PL3781563T3 true PL3781563T3 (pl) 2022-10-03

Family

ID=68322176

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19791794.1T PL3781563T3 (pl) 2018-04-25 2019-04-19 Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie

Country Status (11)

Country Link
US (2) US11999725B2 (pl)
EP (1) EP3781563B1 (pl)
JP (1) JP7212142B2 (pl)
KR (1) KR102926807B1 (pl)
CN (2) CN110396087A (pl)
AU (1) AU2019260159B2 (pl)
BR (1) BR112020021862A2 (pl)
CA (1) CA3097949C (pl)
ES (1) ES2927346T3 (pl)
IL (1) IL278036B2 (pl)
PL (1) PL3781563T3 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
CN113712966A (zh) * 2020-05-26 2021-11-30 格格巫（珠海）生物科技有限公司 一种化合物在预防和治疗动物肿瘤中的应用
CN113797198B (zh) * 2020-06-16 2023-11-28 格格巫（珠海）生物科技有限公司 一种化合物在预防和/或治疗动物的病原体感染中的应用
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
AU2021352535B2 (en) * 2020-09-30 2026-02-12 Beone Medicines I Gmbh 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof
CN114437058A (zh) * 2020-10-30 2022-05-06 珠海宇繁生物科技有限责任公司 氘代hpk1激酶抑制剂及其制备方法和应用
CN114685481A (zh) * 2020-12-31 2022-07-01 南通泰禾化工股份有限公司 一种氟噻唑吡乙酮的制备方法
CN114685489B (zh) * 2020-12-31 2025-03-07 南京再明医药有限公司 多取代含氮杂环类化合物及其应用
CN114907377A (zh) * 2021-02-10 2022-08-16 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2022228489A1 (zh) * 2021-04-29 2022-11-03 贝达药业股份有限公司 Hpk1抑制剂及其在医药上的应用
CN116535422B (zh) * 2022-01-26 2025-04-18 上海交通大学 具有五元芳杂环并哌啶/高哌啶的hpk1抑制剂及其制备方法及用途
CN114767676B (zh) 2022-04-22 2024-04-19 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用
CN119707930A (zh) * 2023-09-28 2025-03-28 甘李药业股份有限公司 芳香环类化合物及其制法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2517256C (en) 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
BRPI0514687A (pt) 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
GB0621607D0 (en) 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CN103965161A (zh) * 2013-02-02 2014-08-06 正大天晴药业集团股份有限公司 取代的2-氨基吡啶类蛋白激酶抑制剂
AU2014211856C1 (en) 2013-02-02 2018-04-12 Centaurus Biopharma Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
US20160158360A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
US10710978B2 (en) 2015-03-31 2020-07-14 Dana-Farber Cancer Institute, Inc. STK4 inhibitors for treatment of hematologic malignancies
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途

Also Published As

Publication number Publication date
AU2019260159A1 (en) 2020-11-26
JP7212142B2 (ja) 2023-01-24
EP3781563B1 (en) 2022-06-29
ES2927346T3 (es) 2022-11-04
CA3097949C (en) 2024-04-23
EP3781563A1 (en) 2021-02-24
CA3097949A1 (en) 2019-10-31
IL278036B1 (en) 2023-10-01
BR112020021862A2 (pt) 2021-01-26
IL278036A (en) 2020-11-30
US20210276994A1 (en) 2021-09-09
JP2021519827A (ja) 2021-08-12
EP3781563A4 (en) 2021-02-24
US11999725B2 (en) 2024-06-04
IL278036B2 (en) 2024-02-01
CN110396088B (zh) 2024-03-12
KR20210005668A (ko) 2021-01-14
KR102926807B1 (ko) 2026-02-13
AU2019260159B2 (en) 2024-06-06
CN110396087A (zh) 2019-11-01
CN110396088A (zh) 2019-11-01
US20240300941A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
PL3781563T3 (pl) Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie
IL287940A (en) Fgfr inhibitors and methods of use thereof
EP4059928A4 (en) Rock inhibitor, preparation method therefor and use thereof
IL289612A (en) Hpk1 inhibitors and uses thereof
IL283592A (en) Inhibitors of apol1 and methods of using same
IL280782A (en) Inhibiting αv β6 integrin
PL3788047T3 (pl) Stałe postacie inhibitora fgfr i sposoby ich otrzymywania
PL3423561T5 (pl) Biomaty grzybów strzępkowych, sposoby ich wytwarzania i sposoby ich zastosowania
PL3788044T3 (pl) Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
IL257203B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PL3509591T3 (pl) Nowe selektywne inhibitory Jak1 i ich zastosowanie
DK3710430T3 (da) Acss2-inhibitorer og fremgangsmåder til anvendelse deraf
EP3423056A4 (en) METHODS OF REGULATING STEM CELL PROLIFERATION / GENERATION OF INNER EAR HEARING CELLS USING GSK-3-ALPHA INHIBITORS
PL3577213T3 (pl) Komórki drobnoustrojów, sposoby ich wytwarzania i ich zastosowania
IL286492A (en) Sialidase-resistant saccharide and method of making and using the same
EP3947366C0 (en) HPK1 INHIBITORS
PL3752251T3 (pl) Inhibitory arginazy i sposoby ich stosowania
PL3429998T3 (pl) Sposób wytwarzania pochodnych chinolin-2-ylo-fenyloaminy oraz jej soli
PL3586071T3 (pl) Szyba zespolona, sposób jej wytwarzania i jej zastosowanie
EP3569592A4 (en) SELECTIVE HDAC6 INHIBITORS, THEIR METHOD OF PREPARATION AND THEIR APPLICATION
PT3481208T (pt) Câmara de amadurecimento e método para o amadurecimento de frutas
PL4046129T3 (pl) Sposób wytwarzania
DK3458615T3 (da) Bioteknologisk fremgangsmåde til fremstilling af acrylamid og relativt ny bakteriestamme
PL3630738T3 (pl) Sposób wytwarzania ozanimodu
IL286485A (en) Pi4-kinase inhibitors and methods of using the same